OBJECTIVES: The aim of the study was to determine the potential population of patients with stable angina pectoris in Belarus who need prescription of ivabradine and setting the amount of the effect of the drug in this group of patients. METHODS: In the research pharmacoeconomic Markov model  of ivabradine application in patients with stable angina, national surveillance data, analysis of  literature have been used. Patients with stable angina after revascularization, patients with contraindications to beta-blocker use, not applying the dihydropyridines and having a contraindication to ivabradine use have been used to determine the target population. The number of prevented or postponed events – PPE - (nonfatal myocardial infarction and unstable angina, cardiovascular death, the number of surgical revascularization) has been calculated. For the potential efficacy of ivabradine use in patients with stable angina and heart rate ≥ 70 bpm calculating the data about efficacy in accordance with the results of the Beautiful study were used RESULTS: The total number of patients with stable angina pectoris in Belarus in 2011 was 242943. The total number of patients with stable angina who have indications for ivabradine was 17559 people. The number of prevented cases of non-fatal myocardial infarction and unstable angina was 244 cases per year. The number of prevented cases of cardiovascular death was 95 cases per year. The number of prevented cases of surgical revascularization was 260 cases per year. CONCLUSIONS: The analysis allowed to identify Belarusian patients in need of  ivabradine use by estimating the size of the target group of patients with stable angina and elevated heart rate for whom antianginal therapy is inadequate or impossible and who need an ivabradine prescription and potentially could make the most effective reaction to the therapy.